title: Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia.
abstract: OBJECTIVE
  To determine the 2-year results of intravitreal bevacizumab in highly myopic eyes with choroidal neovascularization (CNV).
  
  
  METHODS
  An open-label, consecutive, interventional case series. Seventy-five eyes of 69 consecutive Japanese patients with either subfoveal or nonsubfoveal myopic CNVs were studied. The eyes were treated with intravitreal bevacizumab and followed-up for at least 2 years. The best-corrected visual acuities at the baseline in eyes with subfoveal CNV were compared with that in eyes with nonsubfoveal CNV at 2 years after the intravitreal bevacizumab.
  
  
  RESULTS
  The difference between the mean best-corrected visual acuity at the baseline and that at 2 years in eyes with a subfoveal CNV was not significant. However, the mean best-corrected visual acuity in eyes with nonsubfoveal CNV was significantly improved from 0.53 ± 0.36 logarithm of the minimal angle of resolution units (Snellen 20/66) before intravitreal bevacizumab to 0.29 ± 0.36 logMAR units (Snellen 20/40) (P < 0.001) 2 years after intravitreal bevacizumab. The incidence of chorioretinal atrophy after 2 years was 3 of 49 (6.1%) in eyes with nonsubfoveal CNV and 21 of 26 (80.8%) in eyes with which subfoveal CNV (P < 0.001). Furthermore, the chorioretinal atrophy area with nonsubfoveal CNV was 0.05 ± 0.21 mm, which was also significantly smaller than that of subfoveal CNV at 1.76 ± 1.60 mm (P < 0.001).
  
  
  CONCLUSIONS
  Intravitreal bevacizumab is a good treatment for eyes with nonsubfoveal CNV; however, another treatment is necessary for eyes with a subfoveally located CNV.
authors.affiliation: Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan.
authors.forename: Kengo
authors.initials: K
authors.lastname: Hayashi
authors.forename: Noriaki
authors.initials: N
authors.lastname: Shimada
authors.forename: Muka
authors.initials: M
authors.lastname: Moriyama
authors.forename: Wakako
authors.initials: W
authors.lastname: Hayashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Tokoro
authors.forename: Kyoko
authors.initials: K
authors.lastname: Ohno-Matsui
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D044466:Asian People; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D005584:Fovea Centralis; D006801:Humans; D058449:Intravitreal Injections; D007564:Japan; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D011446:Prospective Studies; D012044:Regression Analysis; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab